BR112023025264A2 - Formas farmacêuticas sólidas e regimes posológicos compreendendo (2r,3s,4s,5r)-4-[[3- (3,4-difluoro-2-metóxi-fenil)-4,5-dimetil-5-(trifluorometil) tetra-hidrofuran-2-carbonil]amino ]piridina-2-carboxamida - Google Patents
Formas farmacêuticas sólidas e regimes posológicos compreendendo (2r,3s,4s,5r)-4-[[3- (3,4-difluoro-2-metóxi-fenil)-4,5-dimetil-5-(trifluorometil) tetra-hidrofuran-2-carbonil]amino ]piridina-2-carboxamidaInfo
- Publication number
- BR112023025264A2 BR112023025264A2 BR112023025264A BR112023025264A BR112023025264A2 BR 112023025264 A2 BR112023025264 A2 BR 112023025264A2 BR 112023025264 A BR112023025264 A BR 112023025264A BR 112023025264 A BR112023025264 A BR 112023025264A BR 112023025264 A2 BR112023025264 A2 BR 112023025264A2
- Authority
- BR
- Brazil
- Prior art keywords
- difluoro
- carboxamide
- trifluoromethyl
- carbonyl
- pyridine
- Prior art date
Links
- XSQUJFKRXZMOKA-PAFIKIDNSA-N FC=1C(=C(C=CC=1F)[C@H]1[C@@H](O[C@]([C@H]1C)(C(F)(F)F)C)C(=O)NC1=CC(=NC=C1)C(=O)N)OC Chemical compound FC=1C(=C(C=CC=1F)[C@H]1[C@@H](O[C@]([C@H]1C)(C(F)(F)F)C)C(=O)NC1=CC(=NC=C1)C(=O)N)OC XSQUJFKRXZMOKA-PAFIKIDNSA-N 0.000 title abstract 3
- 239000007787 solid Substances 0.000 title abstract 2
- 229940125904 compound 1 Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000007962 solid dispersion Substances 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Abstract
formas farmacêuticas sólidas e regimes posológicos compreendendo (2r,3s,4s,5r)-4-[[3- (3,4-difluoro-2-metóxi-fenil)-4,5-dimetil-5-(trifluorometil) tetra-hidrofuran-2-carbonil]amino ]piridina-2-carboxamida. a presente invenção refere-se a uma dispersão sólida de (2r,3s,4s,5r)-4-[[3- (3,4-difluoro-2-metóxi-fenil)-4,5-dimetil-5-(trifluorometil) tetra-hidrofuran-2-carbonil]amino]piridina-2-carboxamida (composto 1), definido como aqui descrito, ou um sal farmaceuticamente aceitável do mesmo e um comprimido contendo a dispersão sólida para o tratamento da dor. também aqui divulgado é composto 1 ou um sal farmaceuticamente aceitável do mesmo para uso em um método de tratamento da dor.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163196937P | 2021-06-04 | 2021-06-04 | |
US202163196933P | 2021-06-04 | 2021-06-04 | |
US202163285197P | 2021-12-02 | 2021-12-02 | |
US202163285201P | 2021-12-02 | 2021-12-02 | |
PCT/US2022/032253 WO2022256708A1 (en) | 2021-06-04 | 2022-06-03 | Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023025264A2 true BR112023025264A2 (pt) | 2024-02-20 |
Family
ID=82492526
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023025264A BR112023025264A2 (pt) | 2021-06-04 | 2022-06-03 | Formas farmacêuticas sólidas e regimes posológicos compreendendo (2r,3s,4s,5r)-4-[[3- (3,4-difluoro-2-metóxi-fenil)-4,5-dimetil-5-(trifluorometil) tetra-hidrofuran-2-carbonil]amino ]piridina-2-carboxamida |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP4346818A1 (pt) |
KR (1) | KR20240031299A (pt) |
AU (1) | AU2022284952A1 (pt) |
BR (1) | BR112023025264A2 (pt) |
CA (1) | CA3222197A1 (pt) |
IL (1) | IL308954A (pt) |
TW (1) | TW202317108A (pt) |
WO (1) | WO2022256708A1 (pt) |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
US20020017295A1 (en) | 2000-07-07 | 2002-02-14 | Weers Jeffry G. | Phospholipid-based powders for inhalation |
AU2001275881B2 (en) | 2000-07-10 | 2006-04-06 | Vertex Pharmaceuticals (San Diego) Llc | Ion channel assay methods |
US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6492618B1 (en) | 2000-11-02 | 2002-12-10 | Tri Tool Inc. | Automatic weld head alignment and guidance system and method |
AP2007003887A0 (en) | 2004-07-23 | 2007-02-28 | Pfizer | Pyridine derivatives |
AU2007319580B2 (en) | 2006-10-12 | 2012-11-29 | Xenon Pharmaceuticals Inc. | Use of spiro-oxindole compounds as therapeutic agents |
GEP20125379B (en) | 2007-05-03 | 2012-01-10 | Pfizer Ltd | 2 -pyridine carboxamide derivatives as sodium channel modulators |
RU2518073C2 (ru) | 2008-12-26 | 2014-06-10 | ДАЙНИППОН СУМИТОМО ФАРМА Ко., ЛТД. | Новое бициклическое гетероциклическое соединение |
US9174999B2 (en) | 2009-05-07 | 2015-11-03 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for studying, imaging, and treating pain |
AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
WO2011026240A1 (en) | 2009-09-04 | 2011-03-10 | Zalicus Pharmaceuticals Ltd. | Oxopiperazine derivatives for the treatment of pain and epilepsy |
EP2595989B1 (en) | 2010-05-06 | 2016-07-13 | Vertex Pharmaceuticals Incorporated | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels |
US8916565B2 (en) | 2011-02-02 | 2014-12-23 | Vertex Pharmaceuticals Incorporated | Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels |
US10385070B2 (en) | 2011-02-18 | 2019-08-20 | Vertex Pharmaceuticals Incorporated | Chroman-spirocyclic piperidine amides as modulators of ion channels |
ES2786298T3 (es) | 2011-03-03 | 2020-10-09 | Zalicus Pharmaceuticals Ltd | Inhibidores de benzimidazol del canal de sodio |
US8828996B2 (en) | 2011-03-14 | 2014-09-09 | Vertex Pharmaceuticals Incorporated | Morpholine-spirocyclic piperidine amides as modulators of ion channels |
CA2850925C (en) | 2011-10-26 | 2017-01-10 | Pfizer Limited | (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators |
EP2788332A1 (en) | 2011-12-07 | 2014-10-15 | Amgen, Inc. | Bicyclic aryl and heteroaryl sodium channel inhibitors |
CN104136442B (zh) | 2012-01-16 | 2016-12-21 | 沃泰克斯药物股份有限公司 | 作为离子通道调节剂的吡喃‑螺环哌啶酰胺类 |
JP6002785B2 (ja) | 2012-02-03 | 2016-10-05 | ファイザー・インク | ナトリウムチャネルモジュレーターとしてのベンゾイミダゾールおよびイミダゾピリジン誘導体 |
WO2013131018A1 (en) | 2012-03-02 | 2013-09-06 | Zalicus Pharmaceuticals Ltd. | Biaryl inhibitors of the sodium channel |
US9051311B2 (en) | 2012-03-09 | 2015-06-09 | Amgen Inc. | Sulfamide sodium channel inhibitors |
WO2014120820A1 (en) | 2013-01-31 | 2014-08-07 | Vertex Pharmaceuticals Incorporated | Amides as modulators of sodium channels |
CN105026373B (zh) | 2013-01-31 | 2018-03-30 | 沃泰克斯药物股份有限公司 | 作为钠通道调节剂的吡啶酮酰胺 |
AU2014212426B8 (en) | 2013-01-31 | 2018-05-10 | Vertex Pharmaceuticals Incorporated | Quinoline and Quinoxaline Amides as Modulators of Sodium Channels |
US9776995B2 (en) | 2013-06-12 | 2017-10-03 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
MX364155B (es) | 2013-07-19 | 2019-04-12 | Vertex Pharma | Sulfonamidas como moduladores de canales de sodio. |
AU2014362255B2 (en) | 2013-12-13 | 2019-08-29 | Vertex Pharmaceuticals Incorporated | Prodrugs of pyridone amides useful as modulators of sodium channels |
CA2944549A1 (en) | 2014-04-09 | 2015-10-15 | Siteone Therapeutics, Inc. | 10',11'-modified saxitoxin useful for the treatment of pain |
JP6742331B2 (ja) | 2015-03-02 | 2020-08-19 | アムジエン・インコーポレーテツド | 二環式ケトンスルホンアミド化合物 |
EP3356370B1 (en) | 2015-09-30 | 2021-08-18 | Siteone Therapeutics, Inc. | 11,13-modified saxitoxins for the treatment of pain |
BR112019020111A2 (pt) | 2017-03-29 | 2020-05-05 | Siteone Therapeutics Inc | saxitoxinas 11,13-modificadas para o tratamento de dor |
EP3601290B1 (en) | 2017-03-29 | 2021-11-24 | Siteone Therapeutics, Inc. | 11,13-modified saxitoxins for the treatment of pain |
KR20200006128A (ko) | 2017-05-16 | 2020-01-17 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 조절제로서의 중수소화 피리돈 아미드 및 이의 프로드럭 |
SG11202000230VA (en) | 2017-07-11 | 2020-02-27 | Vertex Pharma | Carboxamides as modulators of sodium channels |
AU2018314837A1 (en) * | 2017-08-11 | 2020-03-26 | Merck Patent Gmbh | Pharmaceutical preparation comprising 3-Fluoro-4-(7-methoxy-3-methyl-8-(1-methyl-1 H-pyrazol-4-yl)-2-oxo-2,3-dihydro-imidazo(4,5-c)quinolin-1 -yl)-benzonitrile |
AU2019301628A1 (en) | 2018-07-09 | 2021-01-28 | Lieber Institute, Inc. | Pyridine carboxamide compounds for inhibiting NaV1.8 |
US20210139456A1 (en) | 2018-07-09 | 2021-05-13 | Lieber Institute, Inc. | Pyridazine compounds for inhibiting nav1.8 |
WO2020072835A1 (en) | 2018-10-03 | 2020-04-09 | Siteone Therapeutics, Inc. | 11,13-modified saxitoxins for the treatment of pain |
JP7288051B2 (ja) | 2018-11-02 | 2023-06-06 | メルク・シャープ・アンド・ドーム・エルエルシー | Nav1.8阻害薬としての2-アミノ-N-ヘテロアリール-ニコチンアミド類 |
WO2020092187A1 (en) | 2018-11-02 | 2020-05-07 | Merck Sharp & Dohme Corp. | 2-amino-n-phenyl-nicotinamides as nav1.8 inhibitors |
EP3907218A4 (en) | 2019-01-04 | 2022-09-21 | Jiangsu Hengrui Medicine Co., Ltd. | 6-OXO-1,6-DIHYDROPYRIDAZINE DERIVATIVE, METHOD FOR PREPARATION AND MEDICAL USE |
US20230062053A1 (en) | 2019-01-10 | 2023-03-02 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
US20220110923A1 (en) | 2019-01-10 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
WO2020151728A1 (zh) | 2019-01-25 | 2020-07-30 | 江苏恒瑞医药股份有限公司 | 2-氧代-1,2-二氢吡啶类衍生物、其制备方法及其在医药上的应用 |
MA56398A (fr) | 2019-06-27 | 2022-05-04 | Glaxosmithkline Ip Dev Ltd | Composés 2,3-dihydroquinazoline en tant qu'inhibiteurs de nav1.8 |
CN112300051A (zh) | 2019-07-31 | 2021-02-02 | 明慧医药(上海)有限公司 | 一种选择性钠通道调节剂及其制备和应用 |
CN112300069A (zh) | 2019-07-31 | 2021-02-02 | 明慧医药(上海)有限公司 | 一种选择性钠通道调节剂及其制备和应用 |
CN112390745B (zh) | 2019-08-19 | 2022-10-21 | 江苏恒瑞医药股份有限公司 | 吡啶烟酰胺类衍生物、其制备方法及其在医药上的应用 |
TW202115038A (zh) | 2019-08-19 | 2021-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 苯甲醯胺稠芳環類衍生物、其製備方法及其在醫藥上的應用 |
CN112441969A (zh) | 2019-08-30 | 2021-03-05 | 明慧医药(上海)有限公司 | 一种选择性钠通道调节剂及其制备和应用 |
WO2021047622A1 (zh) | 2019-09-12 | 2021-03-18 | 上海济煜医药科技有限公司 | 吡啶氮氧化合物及其制备方法和用途 |
KR20220124176A (ko) | 2019-12-06 | 2022-09-13 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 조절제로서의 치환된 테트라하이드로푸란 |
CN111217776A (zh) | 2020-01-19 | 2020-06-02 | 中国人民解放军军事科学院军事医学研究院 | 含苯并杂环结构的酰胺衍生物、组合物和应用 |
AU2021288190A1 (en) | 2020-06-10 | 2022-12-22 | Amgen Inc. | Heteroalkyl dihydroquinoline sulfonamide compounds |
JP2021195368A (ja) | 2020-06-10 | 2021-12-27 | アムジエン・インコーポレーテツド | シクロブチルジヒドロキノリンスルホンアミド化合物 |
JP2021195367A (ja) | 2020-06-10 | 2021-12-27 | アムジエン・インコーポレーテツド | シクロプロピルジヒドロキノリンスルホンアミド化合物 |
JP2023530320A (ja) | 2020-06-17 | 2023-07-14 | メルク・シャープ・アンド・ドーム・エルエルシー | Nav1.8阻害剤としての5-オキソピロリジン-3-カルボキサミド |
MX2022015579A (es) | 2020-06-17 | 2023-01-24 | Merck Sharp & Dohme Llc | 2-oxo-oxazolidin-5-carboxamidas como inhibidores de nav1.8. |
CA3182633A1 (en) | 2020-06-17 | 2021-12-23 | Ashok Arasappan | 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors |
BR112023002659A2 (pt) | 2020-08-14 | 2023-05-02 | Siteone Therapeutics Inc | Inibidores de cetona não hidratados de nav1.7 para o tratamento da dor |
TW202214259A (zh) | 2020-08-19 | 2022-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種選擇性NaV抑制劑的前藥及其晶型 |
WO2022037647A1 (zh) | 2020-08-19 | 2022-02-24 | 江苏恒瑞医药股份有限公司 | 一种选择性Nav抑制剂的结晶形式及其制备方法 |
CN111808019B (zh) | 2020-09-08 | 2020-11-27 | 上海济煜医药科技有限公司 | 一种并环化合物及其应用 |
CN112225695B (zh) | 2020-12-15 | 2021-03-02 | 上海济煜医药科技有限公司 | 一种氮氧化合物及其制备方法和用途 |
CN112457294B (zh) | 2021-01-27 | 2021-06-04 | 上海济煜医药科技有限公司 | 一种作为NaV1.8阻滞剂的化合物及其制备方法和用途 |
-
2022
- 2022-06-03 KR KR1020247000227A patent/KR20240031299A/ko unknown
- 2022-06-03 IL IL308954A patent/IL308954A/en unknown
- 2022-06-03 CA CA3222197A patent/CA3222197A1/en active Pending
- 2022-06-03 WO PCT/US2022/032253 patent/WO2022256708A1/en active Application Filing
- 2022-06-03 BR BR112023025264A patent/BR112023025264A2/pt unknown
- 2022-06-03 EP EP22741050.3A patent/EP4346818A1/en active Pending
- 2022-06-03 AU AU2022284952A patent/AU2022284952A1/en active Pending
- 2022-06-06 TW TW111120909A patent/TW202317108A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
TW202317108A (zh) | 2023-05-01 |
CA3222197A1 (en) | 2022-12-08 |
AU2022284952A1 (en) | 2023-12-14 |
WO2022256708A1 (en) | 2022-12-08 |
IL308954A (en) | 2024-01-01 |
EP4346818A1 (en) | 2024-04-10 |
KR20240031299A (ko) | 2024-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2367471C2 (ru) | Способы лечения интерлейкин-6-зависимых заболеваний | |
Muñoz et al. | Synergism between COX-3 inhibitors in two animal models of pain | |
DE69634609D1 (de) | Analgesiche synergie durch gleichzeitige verabreichung von subanalgesichen doseneines mu-opioidanagonisten und eines kappa - 2- opioidanagonisten | |
BRPI0415649A (pt) | método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica | |
BR112012029959A2 (pt) | compostos de carbamato de mentila como ativos para clareamento de pele e/ou cabelo | |
BRPI0708640A8 (pt) | composição farmacêutica, e, métodos para tratar um paciente com dor de cabeça de enxaqueca, para tratar um paciente com dor e para tratar um paciente com enxaqueca | |
Podkowa et al. | Antidepressant-like effects of scopolamine in mice are enhanced by the group II mGlu receptor antagonist LY341495 | |
BRPI0510895A (pt) | formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t | |
Zarrindast et al. | Nicotinic acetylcholine receptors of the dorsal hippocampus and the basolateral amygdala are involved in ethanol-induced conditioned place preference | |
Sakloth et al. | HDAC6-selective inhibitors decrease nerve-injury and inflammation-associated mechanical hypersensitivity in mice | |
Sałat et al. | Evaluation of cebranopadol, a dually acting nociceptin/orphanin FQ and opioid receptor agonist in mouse models of acute, tonic, and chemotherapy-induced neuropathic pain | |
BR112022011998A2 (pt) | Usos de anticorpos anti-tgfss e inibidores de checkpoint para o tratamento de doenças proliferativas | |
BR0315593A (pt) | Método de tratar, prevenir, modificar ou controlar dor e composição farmacêutica | |
BR112021023110A2 (pt) | Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton | |
BR112022015363A2 (pt) | Uso de um antagonista do receptor de interleucina-4 (il-4r), composição farmacêutica e recipiente para tratar dermatite atópica (da) ou melhorar um parâmetro associado à da em um indivíduo | |
BR112022000382A2 (pt) | Administração de agonista de sting e inibidores de checkpoint | |
BR112021022602A2 (pt) | Métodos para tratamento de urticária espontânea crônica com o uso de um inibidor de tirosina quinase de bruton | |
BR112023025264A2 (pt) | Formas farmacêuticas sólidas e regimes posológicos compreendendo (2r,3s,4s,5r)-4-[[3- (3,4-difluoro-2-metóxi-fenil)-4,5-dimetil-5-(trifluorometil) tetra-hidrofuran-2-carbonil]amino ]piridina-2-carboxamida | |
Weil et al. | The use of lidocaine patches | |
Fenichel et al. | Combination products as first-line pharmacotherapy | |
BR0315609A (pt) | Método de tratar, prevenir, modificar ou controlar dor e composição farmacêutica | |
Wu et al. | Attenuation of toluene-induced brain stimulation reward enhancement and behavioral disturbances by N-acetylcysteine in mice | |
BR112021000183A8 (pt) | Preparação medicinal para uso externo | |
Yeh et al. | Intrathecal pramipexole and selegiline for sensory and motor block in rats | |
BR112023001585A2 (pt) | Composto, e, composição farmacêutica para a prevenção ou tratamento de dor |